VanEck Pharmaceutical ETF PPH
Strategy
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Ticker | Name | Share Class Type | Investment Status | Morningstar Rating for Funds Overall | Medalist Rating Overall | Inception Date | Total Net Assets for Share Class | Adjusted Expense Ratio | Fee Level Distribution | Minimum Initial Investment | 1-Year Net Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|
PPH | VanEck Pharmaceutical ETF | ETF | Open | — | — | 0.360% | — | — | — | ||
| — | VanEck Pharmaceutical ETF | ETF | Open | — | — | 0.360% | — | — | — | ||
PPH | VanEck Pharmaceutical ETF | ETF | Open | $1.10B | 0.360% | — | — | −$372.40M |